Publish in this journal
Journal Information
Vol. 74. Issue 2.
Pages 201 (February 2021)
Download PDF
More article options
Vol. 74. Issue 2.
Pages 201 (February 2021)
Letter to the Editor
DOI: 10.1016/j.rec.2020.09.024
Full text access
Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19. Response
Tratamiento neurohormonal en miocardiopatía de tako-tsubo precipitada por COVID-19. Respuesta
Loreto Oyarzabala,
Corresponding author

Corresponding author:
, Joan Antoni Gómez-Hospitala,b, Josep Comín-Coleta
a Servicio de Cardiología, Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
b Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain
Related content
Rev Esp Cardiol. 2021;74:200-110.1016/j.rec.2020.09.002
Chia Siang Kow, Syed Shahzad Hasan
Article information
Full Text
Download PDF
Full Text
To the Editor,

The neurohormonal treatment received by our patient comprised a beta-blocker, bisoprolol, and an angiotensin-converting enzyme inhibitor (ACE-I), enalapril. At 3 months of follow-up, he had no further episodes of chest pain or signs of heart failure.

As mentioned in the Letter, although treatment with beta-blockers may slow the effect of catecholamine release thought to be the pathophysiological mechanism behind tako-tsubo cardiomyopathy, clinical benefits have not been demonstrated. However, treatment with ACE-I, which has shown improved survival in a registry, could contribute to ventricular remodeling.

In the case of coronavirus disease 2019 (COVID-19), treatment with ACE-I has generated controversy. When the disease first emerged, animal studies1 demonstrated that coronavirus uses angiotensin-converting enzyme 2 (ACE-2), an aminopeptidase with abundant expression in the lungs and heart, as a receptor for cell entry. Treatment with ACE-I increases the expression of ACE-2, leading to the hypothesis that it may affect susceptibility to the infection or its virulence. Later, a case-control study2 with more than 6000 patients found no evidence of an association between these drugs and COVID-19; current protocols therefore recommend continuing treatment with ACE-I in patients with SARS-CoV-2 infection in the absence of other contraindications.

As tako-tsubo cardiomyopathy is a rare complication of SARS-CoV-2 infection, to date there are no specific studies on the recommended treatment. The only treatment with evidence on survival in COVID-19 is corticosteroids3 (dexamethasone), possibly due to its effect on the inflammatory cascade that occurs in this disease. Bearing in mind that the systemic inflammatory status could contribute to the development of tako-tsubo cardiomyopathy, treatment with dexamethasone may affect its onset and outcome, although specific studies are needed to assess this.

M. Paul, A. Poyan Mehr, R. Kreutz.
Physiology of local renin-angiotensin systems.
Physiol Rev., 86 (2006), pp. 747-803
G. Mancia, F. Rea, M. Ludergnani, G. Apolone, G. Corrao.
Renin-angiotensin-aldosterone system blockers and the risk of COVID-19.
The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 — preliminary report. N Engl J Med. 2020.
Copyright © 2020. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?